Lubroth, P;
Colasante, G;
Lignani, G;
(2021)
In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline?
Frontiers in Neuroscience
, 15
, Article 632522. 10.3389/fnins.2021.632522.
Preview |
Text
Lignani_In vivo Genome Editing Therapeutic Approaches for Neurological Disorders- Where Are We in the Translational Pipeline_VoR.pdf - Published Version Download (297kB) | Preview |
Abstract
In vivo genome editing tools, such as those based on CRISPR, have been increasingly utilized in both basic and translational neuroscience research. There are currently nine in vivo non-CNS genome editing therapies in clinical trials, and the pre-clinical pipeline of major biotechnology companies demonstrate that this number will continue to grow. Several biotechnology companies commercializing in vivo genome editing and modification technologies are developing therapies for CNS disorders with accompanying large partnering deals. In this review, the authors discuss the current genome editing and modification therapy pipeline and those in development to treat CNS disorders. The authors also discuss the technical and commercial limitations to translation of these same therapies and potential avenues to overcome these hurdles.
| Type: | Article |
|---|---|
| Title: | In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fnins.2021.632522 |
| Publisher version: | http://dx.doi.org/10.3389/fnins.2021.632522 |
| Language: | English |
| Additional information: | Copyright © 2021 Lubroth, Colasante and Lignani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Experimental Epilepsy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10124157 |
Archive Staff Only
 |
View Item |
